IL158574A0 - Novel pyridyl cyanoguanidine compounds - Google Patents

Novel pyridyl cyanoguanidine compounds

Info

Publication number
IL158574A0
IL158574A0 IL15857402A IL15857402A IL158574A0 IL 158574 A0 IL158574 A0 IL 158574A0 IL 15857402 A IL15857402 A IL 15857402A IL 15857402 A IL15857402 A IL 15857402A IL 158574 A0 IL158574 A0 IL 158574A0
Authority
IL
Israel
Prior art keywords
halogen
alkylcarbonyl
aminoalkyl
formyl
alkoxycarbonyl
Prior art date
Application number
IL15857402A
Other languages
English (en)
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of IL158574A0 publication Critical patent/IL158574A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15857402A 2001-05-24 2002-05-24 Novel pyridyl cyanoguanidine compounds IL158574A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29292801P 2001-05-24 2001-05-24
US29292701P 2001-05-24 2001-05-24
PCT/DK2002/000353 WO2002094813A1 (en) 2001-05-24 2002-05-24 Novel pyridyl cyanoguanidine compounds

Publications (1)

Publication Number Publication Date
IL158574A0 true IL158574A0 (en) 2004-05-12

Family

ID=26967641

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15857402A IL158574A0 (en) 2001-05-24 2002-05-24 Novel pyridyl cyanoguanidine compounds

Country Status (18)

Country Link
US (2) US7304066B2 (xx)
EP (1) EP1397355B1 (xx)
JP (1) JP4429607B2 (xx)
KR (1) KR20030097897A (xx)
CN (1) CN1247570C (xx)
AT (1) ATE442362T1 (xx)
BR (1) BR0209930A (xx)
CA (1) CA2447021C (xx)
CZ (1) CZ20033190A3 (xx)
DE (1) DE60233656D1 (xx)
ES (1) ES2328799T3 (xx)
HK (1) HK1066216A1 (xx)
HU (1) HUP0400021A3 (xx)
IL (1) IL158574A0 (xx)
MX (1) MXPA03010669A (xx)
PL (1) PL366459A1 (xx)
RU (1) RU2292344C2 (xx)
WO (1) WO2002094813A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
CN1918131B (zh) * 2004-02-05 2011-05-04 前体生物药物股份公司 谷氨酰胺酰基环化酶抑制剂
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
ES2572777T3 (es) * 2004-12-22 2016-06-02 Leo Pharma A/S Compuestos novedosos de cianoguanidina
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CN101247804B (zh) 2005-06-30 2012-09-26 史密丝克莱恩比彻姆公司 化学化合物
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AU2009286604B2 (en) 2008-08-29 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Novel urea and thiourea derivatives
CA2751495C (en) * 2009-02-06 2013-08-20 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
WO2011095027A1 (zh) * 2010-02-04 2011-08-11 天津和美生物技术有限公司 吡啶基氰基胍衍生物
CN102740850B (zh) * 2010-02-04 2014-04-02 天津和美生物技术有限公司 吡啶基氰基胍衍生物
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
EP2611778B1 (en) * 2010-09-03 2015-08-05 Forma TM, LLC. Guanidine compounds and compositions for the inhibition of nampt
US8859594B2 (en) 2010-10-26 2014-10-14 Tianjin Hemay Bio-Tech Co., Ltd. Polymorphs of N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine, and preparation thereof and use thereof
EP2649048B1 (en) * 2010-12-09 2016-03-30 Radikal Therapeutics Inc. Multifunctional nitroxide derivatives and uses thereof
BR112014025506B1 (pt) * 2012-04-13 2024-02-06 Epizyme, Inc Composição que compreende composto inibidor de ezh2, uso terapêutico da mesma e método in vitro de inibição da proliferação de células de câncer
KR101656663B1 (ko) 2015-07-27 2016-09-13 충남대학교산학협력단 암 예방 및 치료용 조성물
US11958846B2 (en) 2018-08-17 2024-04-16 Novartis Ag Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
CN110734405A (zh) * 2019-11-11 2020-01-31 华东数字医学工程研究院 一种n-(6-氨己基)-n’-甲基-2,2’-联咪唑的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696140A (en) * 1992-09-15 1997-12-09 Leo Pharmaceutical Products Ltd. N-cyano-N'-pyridylguanidines as serotonin antagonists
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9711119D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711122D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US7129043B1 (en) * 1998-10-22 2006-10-31 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
WO2000061559A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. N-substituted cyanoguanidine compounds
AU4080300A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. Cyanoguanidine compounds
US6645968B2 (en) 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers
ES2292462T3 (es) 1999-08-03 2008-03-16 Abbott Laboratories Agentes abridores de los canales del potasio.

Also Published As

Publication number Publication date
EP1397355A1 (en) 2004-03-17
KR20030097897A (ko) 2003-12-31
JP2005508859A (ja) 2005-04-07
CN1509283A (zh) 2004-06-30
WO2002094813A1 (en) 2002-11-28
EP1397355B1 (en) 2009-09-09
CZ20033190A3 (cs) 2004-06-16
DE60233656D1 (de) 2009-10-22
HUP0400021A2 (hu) 2004-04-28
US20080090842A1 (en) 2008-04-17
ATE442362T1 (de) 2009-09-15
CA2447021C (en) 2010-08-10
PL366459A1 (en) 2005-02-07
JP4429607B2 (ja) 2010-03-10
RU2003137007A (ru) 2005-04-20
US7304066B2 (en) 2007-12-04
CN1247570C (zh) 2006-03-29
RU2292344C2 (ru) 2007-01-27
ES2328799T3 (es) 2009-11-18
HK1066216A1 (en) 2005-03-18
US7807682B2 (en) 2010-10-05
BR0209930A (pt) 2004-03-30
CA2447021A1 (en) 2002-11-28
HUP0400021A3 (en) 2008-03-28
MXPA03010669A (es) 2004-07-01
US20040220408A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
IL158574A0 (en) Novel pyridyl cyanoguanidine compounds
AU2002246728A1 (en) Carboline derivatives
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
MXPA05013142A (es) Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
UA84712C2 (xx) N-заміщені піразоліламідилбензімідазоліли як c-kit інгібітори$n-замещенные пиразолиламидилбензимидазолилы как c-kit ингибиторы
PL377285A1 (pl) Podstawione pochodne pirolo-pirazolowe jako inhibitory kinazy
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
HK1080470B (zh) 雜環化合物
HK1095138A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
MY130697A (en) 4-trifluoromethylpyrazolyl-substituted pyridines and pyrimidines
AU2002249890A1 (en) Carboline derivatives
MXPA04006184A (es) Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
AU2002213421A1 (en) Condensed pyridoindole derivatives
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
AU2002213419A1 (en) Condensed pyridoindole derivatives
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
IL161842A0 (en) 2-Amino-4-heteroarylethyl-thiazoline derivatives and their use as inhibitors of inducible no-synthase